These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21265124)

  • 1. [Experience of using thalidomide in the treatment of patients with multiple myeloma].
    Novosad OI; Kriachok IA; Kadnikova TV; Tytorenko IB; Sychova TV; Kostiukova NI
    Lik Sprava; 2010; (3-4):79-86. PubMed ID: 21265124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
    Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis.
    Kagoya Y; Nannya Y; Kurokawa M
    Leuk Res; 2012 Aug; 36(8):1016-21. PubMed ID: 22579366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
    Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
    Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thalidomide induced peripheral neuropathy in multiple myeloma patients].
    Banach M; Jurczyszyn A; Skotnicki A
    Przegl Lek; 2015; 72(11):629-35. PubMed ID: 27012121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report.
    Eo WK; Kim SH; Cheon SH; Lee SH; Jeong JS; Kim YS; Chang HK; Suh KS; Kim HY
    Ann Hematol; 2010 Apr; 89(4):421-2. PubMed ID: 19693501
    [No Abstract]   [Full Text] [Related]  

  • 7. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
    Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV
    Mayo Clin Proc; 2003 Jan; 78(1):34-9. PubMed ID: 12528875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
    Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
    Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
    Seki JT; Banglawala S; Lentz EM; Reece DE
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
    [No Abstract]   [Full Text] [Related]  

  • 10. Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
    Mangiacavalli S; Albani G; Caravita T; Cocito F; Pascutto C; Zappasodi P; Bringhen S; Palumbo A; Cazzola M; Corso A
    Leuk Lymphoma; 2012 Mar; 53(3):514-5. PubMed ID: 22141736
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of thalidomide in multiple myeloma.
    Schwab C; Jagannath S
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide, a thalidomide derivative, shows promise in various applications.
    Oestreicher P
    ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
    [No Abstract]   [Full Text] [Related]  

  • 13. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide in the treatment of multiple myeloma.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide dosing in patients with relapsed or refractory multiple myeloma.
    Thompson JL; Hansen LA
    Ann Pharmacother; 2003 Apr; 37(4):571-6. PubMed ID: 12659617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
    Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features.
    Isoardo G; Bergui M; Durelli L; Barbero P; Boccadoro M; Bertola A; Ciaramitaro P; Palumbo A; Bergamasco B; Cocito D
    Acta Neurol Scand; 2004 Mar; 109(3):188-93. PubMed ID: 14763956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attainment of a stringent complete response in multiple myeloma with thalidomide monotherapy.
    Aritaka N; Ichikawa K; Nakamura H; Yasuda H; Ogura K; Matsumoto T; Komatsu N; Hirano T
    Intern Med; 2012; 51(19):2781-3. PubMed ID: 23037474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
    Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
    Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Plasmati R; Cangini D; Tacchetti P; Perrone G; Pastorelli F; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2005 Mar; 74(3):212-6. PubMed ID: 15693790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.